3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Cyclophosphamide
9
Melphalan
8
X-Rays
7
Specimen Handling
7
Phantoms, Imaging
7
Magnetic Resonance Spectroscopy
7
Busulfan
7
Flow Cytometry
6
Filgrastim
6
Nuclear Medicine Department, Hospital
5
Methylprednisolone
5
Carboplatin
5
Biopsy
5
Therapeutics
4
Radiotherapy
4
Psychiatric Rehabilitation
4
Ipilimumab
4
Etoposide
4
Antilymphocyte Serum
4
Alemtuzumab
4
fludarabine
3
Topotecan
3
Thiotepa
3
Stem Cell Transplantation
3
Polymerase Chain Reaction
3
Peripheral Blood Stem Cell Transplantation
3
Nivolumab
3
Immunologic Techniques
3
Crizotinib
3
Caspofungin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroblastoma
×
bempegaldesleukin
×
Lymphoid
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts